MedPath

Comparing the level of protection induced by giving two different vaccination schedules for dog bites among healthy volunteers in India. A multi Centre study

Phase 4
Registration Number
CTRI/2023/10/058418
Lead Sponsor
Indian Council of Medical Research
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
ot Yet Recruiting
Sex
Not specified
Target Recruitment
0
Inclusion Criteria

a) Healthy males or females

b) Aged between 18 to 45 years

c) Willing to give blood samples on days 0,14,28,42,180 and 365

Exclusion Criteria

a) History of dog bite

b) History of rabies immunization

c) Anti-malarial drug treatment during the last two months

d) Treatment with parenteral or oral steroids / immunosuppressive drugs during the last two months

e) Receiving immunoglobulins

f) Suffering from an autoimmune disease or any other immunological disorder

g) History of hypersensitivity to any vaccine

h) History of drug abuse or alcohol abuse

i) Psychological condition rendering the volunteer unable to understand the nature, scope, and consequence of the study

j) Participation in other investigational trials at the same time

k) Pregnant women and lactating mothers

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
The Primary outcome measure will be geometric mean titres of Rabies Virus Neutralizing Antibody on Day 42 from the start of the vaccination scheduleTimepoint: On Day 42 from the start of the vaccination schedule
Secondary Outcome Measures
NameTimeMethod
Geometric mean titres of Rabies Virus Neutralizing Antibody ConcentrationsTimepoint: on Day Days 14, 28, 180 & 365 from start of the vaccination schedule;Safety outcome measures will comprise of solicited post-vaccination reactions, vaccine-related SAEs, & unsolicited vaccine-related AEsTimepoint: pre-defined time points from vaccination till 4 weeks after last vaccine dose.;Seroconversion rates (Rabies Virus Neutralizing Antibody Concentrations Equal & Above 0.5 IU/ml)Timepoint: on Days 14, 28, 42, 180 & 365 from the start of the vaccine schedule
© Copyright 2025. All Rights Reserved by MedPath